ESTIMATION OF EFFICIENCY OF TRANSIT FIBROELASTROMETRY IN NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH OBESITY

The purpose of the study: to evaluate the effectiveness of the use of transient liver fibroelastometry (TLF) in the determination of the stage of liver fibrosis (LF) in patients with non-alcoholic fatty liver disease (NAFLD) and obesity using XL- and M-sensors. Materials and methods: 110 patients with NAFLD were examined at different stages of the disease at the age of 29 to 82 years. The average BMI is 30.35 ± 5.35. The diagnosis is based on standard laboratory and instrumental data, assessment of the degree of steatosis depending on the stage of ultrasound and liver fibrosis on device for noninvasive determination of the degree of liver fibrosis and using XL and M sensors, using a puncture liver biopsy. Results: In patients with NAFLD and BMI more than 31.5 kg / cm2, when performing an M-sensor study, the number of studies with IqR> 30% (with low reliability) was more than 80%. In patients with NAFLD and BMI more than 31.5 kg / cm² when performing an XL-sensor, the number of studies with IqR> 30% was 4%. The sensitivity of the method ranges from 0.73 at the stage of F 2-3 on the METAVIR scale and 0.89 at F4, the specificity from 0.7 at F2-3 to 0.77 at F4. AUROC as a whole 0,8 that speaks about good reliability of a method. Conclusions: patients with NAFLD and BMI 30.35 ± 5.36 recommended to perform TLF using an XL-sensor. A BMI of 39 kg / m² or more is an absolute limitation for performing TLF.

M-датчик, XL-датчик, transient fibroelastometry of the liver, M-sensor, XL-sensor, liver fibrosis, non-alcoholic fatty liver disease, body mass index

1. Wong R.J, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017 Nov;46 (10):974-980. https://doi.org/10.1111/apt.14327

2. Rich N.E, Oji S, Mufti A.R, Browning J.D, Parikh N.D, Odewole M., Mayo H., Singal A.G. Racial and Ethnic Disparities in Non-alcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Sep 29. pii: S1542-3565 https://doi.org/10.1016/j.cgh.2017.09.041

3. Драпкина О.М., Смирин В. И., Ивашкин В. Т. НАЖБП. Современный взгляд на проблему. Лечащий врач 2010; 5(5):57-61

4. Ивашкин В.Т., Драпкина О. М., Маев И. В., Трухманов А. С., Блинов Д. В., Пальгова Л. К., Цуканов В. В., Ушакова Т. И. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2016, № 6, с 31-41

5. Rinella M. E. Nonalcoholic fatty liver disease: a systematic review.// JAMA 2015. V.313. P. 2263-2273. https://doi.org/10.1001/jama.2015.5370

6. Бакулин И.Г., Сандлер Ю. Г., Винницкая Е. В., Кейян В. А., Родионова С. В., Ротин Д. Л. Cахарный диабет и НАЖБП: грани сопряженности. Терапевтический архив 2017 Т 89, № 2, с 59-65. doi: 10.17116/terarkh201789259-65

7. Wong V.W, Wong G.L, Choi P.C, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.// Gut 2010;59:969-74. http://doi/10.1002/hep4.1134/full

8. Ascha M.S., Hanouneh I. A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. // Hepatology 2010; 51: 1972-8. https://dx.doi.org/10.4254%2Fwjh.v9.i7.385

9. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-16. https://doi.org/10.1002/hep.24491

10. Younossi Z.M., Otgonsuren M., Henry L., Venkatesan C., Mishra A., Erario M., Hunt S. Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009. Hepatology 2015 Aug 14. http://doi.org/10.1002/hep.28123

11. David Sherman; Phillip Lung, Philip Shorvon. Virtual Touch Quantification Elastography for Non-invasive Assessment of Liver Disease and Its Complications. What the Clinical Needs to Know..//Frontline Gastroenterology,2017;8(1): 37-44. https://dx.doi.org/10.1136%2Fflgastro-2016-100729

12. Постнова Н.А., Борсуков А. В., Морозова Т. Г.и др. Компрессионная эластография печени: методика, особенности получения эластограмм, анализ ошибок и артефактов // Радиология-практика. 2015.№ 2 (50). С. 45-54

13. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography// J. Hepatol. - 2008. - V. 48. - P. 835-847. https://doi.org/10.1016/j.jhep.2008.02.008

14. EASL-ALEH Clinical Practice Guidelines: Noninvasive tests for evaluation of liver disease severity and prognosis // Journal of Hepatology. 2015. - Vol. 63. - P. 237-264. https://doi.org/10.1016/j.jhep.2015.04.006